Where Espansione's Technology Is Applied

Espansione's two core technologies, LM™ LLLT photobiomodulation and OPE™ IPL, are not tied to a single disease. Because they act on shared biological mechanisms, energy, perfusion and inflammation, they apply across several clinical domains. This page maps those areas and links to the detail within each.

Anterior-segment ophthalmology

The foundation of the platform is the front of the eye: dry eye disease, meibomian gland dysfunction, ocular surface disease and lid-margin conditions. This is where the evidence base is most mature and where TFOS DEWS III recognises light therapy across all three driver groups. See anterior-segment applications.

Retina (posterior segment)

In the back of the eye, photobiomodulation is being used and studied for dry age-related macular degeneration, addressing an unmet need where no standard treatment exists for the early and intermediate stages. See retinal applications.

Surgical and perioperative care

Around cataract and refractive surgery, the platform supports the ocular surface before and after the procedure, improving measurement reliability and easing recovery. See surgical and perioperative applications.

Dermatology and aesthetics

Beyond the eye, the same technologies serve the skin through dedicated devices, addressing redness, pigmentation and the signs of aging. See dermatology applications.

A platform, not a point solution

What unites these areas is a single therapeutic principle applied with precision across different tissues. The breadth is possible because the mechanism of action is biological and shared, not specific to one disease. Indications and clearances vary by region.

Not all solutions and indications are cleared in all countries and for all cohorts. Every piece of information ought to be considered as fact-based evidence deriving from publicly available literature, for the sole purpose of scientific exchange.